| 0 (0%) | 09-27 09:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.66 | 1-year : | 0.77 |
| Resists | First : | 0.56 | Second : | 0.66 |
| Pivot price | 0.5 |
|||
| Supports | First : | 0.49 | Second : | 0.45 |
| MAs | MA(5) : | 0.52 |
MA(20) : | 0.51 |
| MA(100) : | 0.48 |
MA(250) : | 0.62 |
|
| MACD | MACD : | 0 |
Signal : | 0  |
| %K %D | K(14,3) : | 70.2 |
D(3) : | 73.5 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 1.16 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PHGE ] has closed below upper band by 42.9%. Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.54 - 0.54 | 0.54 - 0.54 |
| Low: | 0.49 - 0.49 | 0.49 - 0.5 |
| Close: | 0.5 - 0.51 | 0.51 - 0.52 |
Wed, 17 Sep 2025
Valuation Update: Is PHGE benefiting from innovation trends - July 2025 Sentiment & Low Risk High Reward Ideas - خودرو بانک
Tue, 19 Aug 2025
FDA Places Clinical Hold on BiomX's Cystic Fibrosis Trial BX004 - European Study Continues Unaffected - Stock Titan
Wed, 13 Aug 2025
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates - GlobeNewswire
Wed, 13 Aug 2025
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates - TradingView
Wed, 13 Aug 2025
BiomX Inc (PHGE) Reports Q2 2025 EPS of -$0.33, Net Loss of $6 M - GuruFocus
Wed, 06 Aug 2025
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 18 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 12.9 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 81 (K) |
| EPS | -3.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.7 % |
| Return on Equity (ttm) | -121.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.14 |
| PEG Ratio | 0 |
| Price to Book value | -0.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|